Reports Q3 revenue $9.5B, consensus $8.95B. “Lilly had another strong quarter in Q3 as Mounjaro and Verzenio continued to gain momentum,” said David Ricks, Lilly’s chair and CEO. “Lilly executed on business development priorities in the third quarter, including multiple acquisitions that expand our already robust pipeline. We remain focused on growth and delivering new, innovative medicines that make life better for millions of patients around the globe.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Delivers Robust Q3 Sales Growth
- Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
- Notable companies reporting before tomorrow’s open
- Lilly Declares Fourth-Quarter 2023 Dividend
- Verve Therapeutics, Eli Lilly expand relationship